<p>BioCryst Pharmaceuticals, Inc.（納斯達克代碼：BCRX - 獲取免費報告）內部人士 Alane Barnes 於 12 月 2 日（星期二）出售了 50,906 股 BioCryst Pharmaceuticals 股票。該股票的平均售價為 7.21 美元，總價值為 367,032.26 美元。交易完成後，該內部人士持有公司 365,246 股股票，價值為 2,633,423.66 美元。此次交易使其持股減少了 12.23%。該出售在向 SEC 提交的文件中披露，相關文件可通過此鏈接訪問。</p>
<h2>BioCryst Pharmaceuticals 股票上漲 9.6%</h2>
<p>在週三的午盤交易中，BioCryst Pharmaceuticals 股票上漲 0.69 美元，達到 7.85 美元。該公司的股票交易量為 7,602,203 股，而其平均交易量為 4,026,871 股。該公司的 50 日簡單移動平均為 7.12 美元，200 日簡單移動平均為 8.38 美元。公司市值為 16.5 億美元，市盈率為-157.00，貝塔值為 0.91。BioCryst Pharmaceuticals, Inc.的 52 周最低價為 6.00 美元，52 周最高價為 11.31 美元。</p>
<p>BioCryst Pharmaceuticals（納斯達克代碼：BCRX - 獲取免費報告）於 11 月 3 日（星期一）發佈了季度財報。該生物技術公司報告本季度每股收益為 0.06 美元，低於市場共識預期的 0.07 美元（差額為 0.01 美元）。BioCryst Pharmaceuticals 的股本回報率為-4.24%，淨利潤率為-1.46%。該公司本季度的收入為 1.594 億美元，而分析師預期為 1.6291 億美元。去年同期，該公司每股收益為-0.07 美元。公司的季度收入同比增長 36.1%。整體來看，股票分析師預測 BioCryst Pharmaceuticals, Inc.本年度每股收益將為-0.36 美元。</p>
<h2>華爾街分析師觀點</h2>
<p>幾位分析師對 BCRX 股票發表了看法。Weiss Ratings 在週二的報告中重新發布了 BioCryst Pharmaceuticals 的 “賣出（e+）” 評級。Needham &amp; Company LLC 將 BioCryst Pharmaceuticals 的目標價從 20.00 美元下調至 18.00 美元，並在 11 月 4 日的研究報告中給予該公司 “買入” 評級。Evercore ISI 在 10 月 1 日的報告中重申了 “持平” 評級，並對 BioCryst Pharmaceuticals 的股票設定了 8.00 美元的目標價。Citizens Jmp 在 11 月 5 日的報告中將 BioCryst Pharmaceuticals 的目標價從 27.00 美元下調至 25.00 美元，並對該股票設定了 “市場表現優於大盤” 的評級。最後，JMP Securities 在 10 月 15 日的研究報告中將 BioCryst Pharmaceuticals 的目標價從 17.00 美元上調至 27.00 美元，並給予該股票 “市場表現優於大盤” 的評級。十位投資分析師對該股票給予了 “買入” 評級，三位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “適度買入”，共識目標價為 19.33 美元。</p>
<p><strong>查看我們關於 BioCryst Pharmaceuticals 的最新研究報告</strong></p>
<h2>BioCryst Pharmaceuticals 的機構交易</h2>
<p>機構投資者和對沖基金最近增加或減少了對該公司的投資。安聯資產管理公司在第一季度將其在 BioCryst Pharmaceuticals 的持股增加了 9.6%。安聯資產管理公司目前持有 13,700 股該生物技術公司的股票，價值為 103,000 美元，此前在該期間內又購買了 1,200 股。Universal Beteiligungs und Servicegesellschaft mbH 在第二季度將其在 BioCryst Pharmaceuticals 的持股增加了 7.7%。Universal Beteiligungs und Servicegesellschaft mbH 目前持有 17,992 股該生物技術公司的股票，價值為 161,000 美元，此前在上個季度又收購了 1,288 股。加拿大皇家銀行在第一季度將其在 BioCryst Pharmaceuticals 的持股增加了 2.4%。加拿大皇家銀行目前持有 63,463 股該生物技術公司的股票，價值為 476,000 美元，此前在上個季度又購買了 1,458 股。Captrust Financial Advisors 在第二季度將其在 BioCryst Pharmaceuticals 的持股增加了 7.4%。Captrust Financial Advisors 目前持有 22,105 股該生物技術公司的股票，價值為 198,000 美元，此前在上個季度又收購了 1,527 股。最後，Main Management ETF Advisors LLC 在第二季度將其在 BioCryst Pharmaceuticals 的持股增加了 1.7%。Main Management ETF Advisors LLC 目前持有 112,128 股該生物技術公司的股票，價值為 1,005,000 美元，此前在該期間內又收購了 1,824 股。85.88% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 BioCryst Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>BioCryst Pharmaceuticals, Inc.是一家生物技術公司，開發口服小分子和蛋白質治療藥物以治療罕見疾病。該公司銷售 peramivir 注射液，這是一種用於治療急性非複雜流感的靜脈神經氨酸酶抑制劑，品牌名為 RAPIVAB、RAPIACTA 和 PERAMIFLU；以及 ORLADEYO，一種用於治療遺傳性血管性水腫的口服絲氨酸蛋白酶抑制劑。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 BioCryst Pharmaceuticals</li>
<li>精通紀律：克服交易中的情緒挑戰</li>
<li>3 只有望受益於谷歌 AI 突破的股票</li>
<li>投資者需要了解的擊敗市場的信息</li>
<li>超越 NVIDIA：5 只預計在 2026 年主導市場的半導體股票</li>
<li>道瓊斯狗策略是什麼？概述和示例</li>
<li>3 只你會希望在 2026 年前買入的股票</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 BioCryst Pharmaceuticals 嗎？</h2>
<p>在考慮 BioCryst Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 BioCryst Pharmaceuticals 並不在名單上。</p>
<p>雖然 BioCryst Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

BioCryst制藥

<p>BioCryst 製藥的內部人士 Alane Barnes 以每股 7.21 美元的價格出售了 50,906 股，總計 367,032.26 美元，減少了她的持股比例 12.23%。出售後，她持有 365,246 股，價值 2,633,423.66 美元。此次出售在 SEC 文件中披露。BioCryst 的股票上漲了 9.6%，達到 7.85 美元，交易量為 760 萬股。分析師的評級意見不一，普遍目標價為 19.33 美元。機構投資者已調整了在該公司的持股</p>

<p>BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 50,906 shares of BioCryst Pharmaceuticals stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $7.21, for a total value of $367,032.26. Following the completion of the transaction, the insider owned 365,246 shares of the company's stock, valued at $2,633,423.66. The trade was a 12.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.</p>
<div class="lb-trans"><p>BioCryst Pharmaceuticals, Inc.（納斯達克代碼：BCRX - 獲取免費報告）內部人士 Alane Barnes 於 12 月 2 日（星期二）出售了 50,906 股 BioCryst Pharmaceuticals 股票。該股票的平均售價為 7.21 美元，總價值為 367,032.26 美元。交易完成後，該內部人士持有公司 365,246 股股票，價值為 2,633,423.66 美元。此次交易使其持股減少了 12.23%。該出售在向 SEC 提交的文件中披露，相關文件可通過此鏈接訪問。</p>
</div><h2>BioCryst Pharmaceuticals Stock Up 9.6%</h2>
<div class="lb-trans"><h2>BioCryst Pharmaceuticals 股票上漲 9.6%</h2>
</div><p>BioCryst Pharmaceuticals stock traded up $0.69 during midday trading on Wednesday, reaching $7.85. The company's stock had a trading volume of 7,602,203 shares, compared to its average volume of 4,026,871. The business has a 50-day simple moving average of $7.12 and a 200-day simple moving average of $8.38. The company has a market cap of $1.65 billion, a P/E ratio of -157.00 and a beta of 0.91. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.31.</p>
<div class="lb-trans"><p>在週三的午盤交易中，BioCryst Pharmaceuticals 股票上漲 0.69 美元，達到 7.85 美元。該公司的股票交易量為 7,602,203 股，而其平均交易量為 4,026,871 股。該公司的 50 日簡單移動平均為 7.12 美元，200 日簡單移動平均為 8.38 美元。公司市值為 16.5 億美元，市盈率為-157.00，貝塔值為 0.91。BioCryst Pharmaceuticals, Inc.的 52 周最低價為 6.00 美元，52 周最高價為 11.31 美元。</p>
</div><p>BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The firm had revenue of $159.40 million for the quarter, compared to analyst estimates of $162.91 million. During the same period last year, the firm earned ($0.07) EPS. The company's quarterly revenue was up 36.1% on a year-over-year basis. As a group, equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.</p>
<div class="lb-trans"><p>BioCryst Pharmaceuticals（納斯達克代碼：BCRX - 獲取免費報告）於 11 月 3 日（星期一）發佈了季度財報。該生物技術公司報告本季度每股收益為 0.06 美元，低於市場共識預期的 0.07 美元（差額為 0.01 美元）。BioCryst Pharmaceuticals 的股本回報率為-4.24%，淨利潤率為-1.46%。該公司本季度的收入為 1.594 億美元，而分析師預期為 1.6291 億美元。去年同期，該公司每股收益為-0.07 美元。公司的季度收入同比增長 36.1%。整體來看，股票分析師預測 BioCryst Pharmaceuticals, Inc.本年度每股收益將為-0.36 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Several analysts have weighed in on BCRX shares. Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of BioCryst Pharmaceuticals in a report on Tuesday. Needham &amp; Company LLC dropped their price objective on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday, November 4th. Evercore ISI restated an &#34;in-line&#34; rating and issued a $8.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. Citizens Jmp reduced their target price on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a &#34;market outperform&#34; rating on the stock in a report on Wednesday, November 5th. Finally, JMP Securities boosted their target price on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a &#34;market outperform&#34; rating in a research report on Wednesday, October 15th. Ten investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $19.33.</p>
<div class="lb-trans"><p>幾位分析師對 BCRX 股票發表了看法。Weiss Ratings 在週二的報告中重新發布了 BioCryst Pharmaceuticals 的 “賣出（e+）” 評級。Needham &amp; Company LLC 將 BioCryst Pharmaceuticals 的目標價從 20.00 美元下調至 18.00 美元，並在 11 月 4 日的研究報告中給予該公司 “買入” 評級。Evercore ISI 在 10 月 1 日的報告中重申了 “持平” 評級，並對 BioCryst Pharmaceuticals 的股票設定了 8.00 美元的目標價。Citizens Jmp 在 11 月 5 日的報告中將 BioCryst Pharmaceuticals 的目標價從 27.00 美元下調至 25.00 美元，並對該股票設定了 “市場表現優於大盤” 的評級。最後，JMP Securities 在 10 月 15 日的研究報告中將 BioCryst Pharmaceuticals 的目標價從 17.00 美元上調至 27.00 美元，並給予該股票 “市場表現優於大盤” 的評級。十位投資分析師對該股票給予了 “買入” 評級，三位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “適度買入”，共識目標價為 19.33 美元。</p>
</div><p><strong>View Our Latest Research Report on BioCryst Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 BioCryst Pharmaceuticals 的最新研究報告</strong></p>
</div><h2>Institutional Trading of BioCryst Pharmaceuticals</h2>
<div class="lb-trans"><h2>BioCryst Pharmaceuticals 的機構交易</h2>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Allianz Asset Management GmbH raised its stake in BioCryst Pharmaceuticals by 9.6% during the 1st quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company's stock valued at $103,000 after purchasing an additional 1,200 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH grew its position in BioCryst Pharmaceuticals by 7.7% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 17,992 shares of the biotechnology company's stock worth $161,000 after acquiring an additional 1,288 shares in the last quarter. Royal Bank of Canada increased its position in BioCryst Pharmaceuticals by 2.4% during the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company's stock worth $476,000 after buying an additional 1,458 shares during the last quarter. Captrust Financial Advisors raised its stake in shares of BioCryst Pharmaceuticals by 7.4% in the 2nd quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company's stock valued at $198,000 after acquiring an additional 1,527 shares in the last quarter. Finally, Main Management ETF Advisors LLC boosted its holdings in BioCryst Pharmaceuticals by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 112,128 shares of the biotechnology company's stock valued at $1,005,000 after acquiring an additional 1,824 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近增加或減少了對該公司的投資。安聯資產管理公司在第一季度將其在 BioCryst Pharmaceuticals 的持股增加了 9.6%。安聯資產管理公司目前持有 13,700 股該生物技術公司的股票，價值為 103,000 美元，此前在該期間內又購買了 1,200 股。Universal Beteiligungs und Servicegesellschaft mbH 在第二季度將其在 BioCryst Pharmaceuticals 的持股增加了 7.7%。Universal Beteiligungs und Servicegesellschaft mbH 目前持有 17,992 股該生物技術公司的股票，價值為 161,000 美元，此前在上個季度又收購了 1,288 股。加拿大皇家銀行在第一季度將其在 BioCryst Pharmaceuticals 的持股增加了 2.4%。加拿大皇家銀行目前持有 63,463 股該生物技術公司的股票，價值為 476,000 美元，此前在上個季度又購買了 1,458 股。Captrust Financial Advisors 在第二季度將其在 BioCryst Pharmaceuticals 的持股增加了 7.4%。Captrust Financial Advisors 目前持有 22,105 股該生物技術公司的股票，價值為 198,000 美元，此前在上個季度又收購了 1,527 股。最後，Main Management ETF Advisors LLC 在第二季度將其在 BioCryst Pharmaceuticals 的持股增加了 1.7%。Main Management ETF Advisors LLC 目前持有 112,128 股該生物技術公司的股票，價值為 1,005,000 美元，此前在該期間內又收購了 1,824 股。85.88% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About BioCryst Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 BioCryst Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.</p>
<div class="lb-trans"><p>BioCryst Pharmaceuticals, Inc.是一家生物技術公司，開發口服小分子和蛋白質治療藥物以治療罕見疾病。該公司銷售 peramivir 注射液，這是一種用於治療急性非複雜流感的靜脈神經氨酸酶抑制劑，品牌名為 RAPIVAB、RAPIACTA 和 PERAMIFLU；以及 ORLADEYO，一種用於治療遺傳性血管性水腫的口服絲氨酸蛋白酶抑制劑。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than BioCryst Pharmaceuticals</li>
<li>Mastering Discipline: Overcoming Emotional Challenges In Trading</li>
<li>3 Stocks Poised to Benefit From Google’s AI Breakthough</li>
<li>What Investors Need to Know to Beat the Market</li>
<li>Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026</li>
<li>What is the Dogs of the Dow Strategy? Overview and Examples</li>
<li>3 Stocks You’ll Wish You Bought Before 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 BioCryst Pharmaceuticals</li>
<li>精通紀律：克服交易中的情緒挑戰</li>
<li>3 只有望受益於谷歌 AI 突破的股票</li>
<li>投資者需要了解的擊敗市場的信息</li>
<li>超越 NVIDIA：5 只預計在 2026 年主導市場的半導體股票</li>
<li>道瓊斯狗策略是什麼？概述和示例</li>
<li>3 只你會希望在 2026 年前買入的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in BioCryst Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 BioCryst Pharmaceuticals 嗎？</h2>
</div><p>Before you consider BioCryst Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 BioCryst Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 BioCryst Pharmaceuticals 並不在名單上。</p>
</div><p>While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 BioCryst Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

內幕交易：BioCryst 製藥（NASDAQ:BCRX）的一位內部人士出售了 50,906 股股票